Compare NEN & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership
Current Price
Current Price
| Metric | NEN | NKTX |
|---|---|---|
| Founded | 1977 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building operators | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.0M | 198.2M |
| IPO Year | 1995 | 2020 |
| Metric | NEN | NKTX |
|---|---|---|
| Price | $56.00 | $2.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $11.33 |
| AVG Volume (30 Days) | 487.0 | ★ 636.3K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.71% | N/A |
| EPS Growth | N/A | ★ 11.88 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $89,196,544.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.68 | ★ N/A |
| Revenue Growth | ★ 10.76 | N/A |
| 52 Week Low | $55.61 | $1.70 |
| 52 Week High | $73.50 | $3.72 |
| Indicator | NEN | NKTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.00 | 46.38 |
| Support Level | $55.81 | $2.32 |
| Resistance Level | $60.90 | $2.43 |
| Average True Range (ATR) | 0.62 | 0.14 |
| MACD | -0.03 | 0.04 |
| Stochastic Oscillator | 12.67 | 74.71 |
New England Realty Associates LP is engaged in the business of acquiring, developing, holding for investment, operating, and selling real estate. The Partnership owns and operates various residential apartments, condominium units, and commercial properties located in Massachusetts and New Hampshire. The company generates revenue from rental income from residential and commercial properties recognized over the term of the related lease. The long-term goals of the Partnership are to manage, rent, and improve its properties and to acquire additional properties with income and capital appreciation potential as suitable opportunities arise.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.